MedPAC Weighs High-Profile Reference-Pricing, Arbitration Policies

By Rachel Cohrs / March 7, 2019 at 5:40 PM
Congressional Medicare advisers Thursday (March 7) debated the merits of two of Washington’s hottest drug-pricing policy topics: reference pricing and binding arbitration. The Trump administration is pushing for international reference pricing in Medicare Part B, and top congressional Democrats reportedly are considering arbitration as a tool to lower drug prices. “I think it is really important for us to be as thorough as possible in fleshing out these two options because they are both under serious consideration,” said Medicare Payment...

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.